<DOC>
	<DOCNO>NCT00902135</DOCNO>
	<brief_summary>Aim BETAPATH study evaluate whether use personal digital assistant ( PDA ) improve adherence Multiple Sclerosis patient therapy Betaseron . The Personal digital assistant PDA function electronic diary injection reminder .</brief_summary>
	<brief_title>Injection Management With Betaferon : Influence Adherence , Patients Satisfaction Health Related Outcomes ( BETAPATH )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<criteria>Outpatients diagnosis Multiple Sclerosis decision investigator prescribe Betaferon.The decision treatment type duration take offer patient possibility participate study . Patients , meet Clinically Isolated Syndrome ( CIS ) Relapsing/Remitting Multiple Sclerosis ( RRMS ) criterion , include . Exclusion criterion must read conjunction German product information .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Interferon beta-1b</keyword>
</DOC>